Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-26 08:27:30 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Sebi issues Rs 2
- Sebi looking to mandate FPIs to use RFQ platform for 10 per cent of secondary transactions
- Magnitude 5 earthquake strikes Afghan-Tajikistan border region
- Markets maintain positive trend for six weeks, 4% away from record-high; global cues, earnings to drive markets
- Rupee falls 7 paise to close at 81
- Mahindra World City Developers to invest Rs 1k crore in Tamil Nadu
- Market capitalisation of BSE-listed firms jumps to record high of Rs 355 lakh crore; investors richer by Rs 3
- Rupee falls 2 paise to close at all-time low of 83
- Macro data, global trends to guide markets this week- Analysts